» Articles » PMID: 2659528

Monoclonal Antibody-mediated Protection and Neutralization of Motility in Experimental Proteus Mirabilis Infection

Overview
Journal Infect Immun
Date 1989 Jul 1
PMID 2659528
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

A panel of monoclonal antibodies with specificity for a wound isolate of Proteus mirabilis was established. Of nine antibodies studied in detail, three were broadly reactive with various Proteus isolates, while six reacted in a serotype-specific fashion with the strain used for immunization. Five of the six serotype-specific antibodies were reactive with lipopolysaccharide. The sixth serotype-specific antibody, 4-F (immunoglobulin G1 [IgG1]), was potently protective in a burn wound sepsis model and recognized a protein antigen. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blot (immunoblot) analysis were used to determine that 4-F was reactive with flagellar protein. Approximately 1.3 micrograms of the antibody was sufficient to provide protection against 8 50% lethal doses of wound isolate, and approximately 26 micrograms provided full protection against challenge with 333 50% lethal doses. In vitro test results indicated that 4-F inhibited the motility of the wound isolate, and in vivo testing showed that it inhibited dissemination of the inoculum from the burn site to the liver and spleen. Whereas the antibody was highly effective in preventing the death of mice subsequent to challenge at a burn site, no protection was seen following an intraperitoneal challenge. These results may therefore indicate that the protection observed in the burn model is solely a reflection of the capacity of 4-F to neutralize bacterial motility.

Citing Articles

Secondary metabolites produced by marine streptomyces as antibiofilm and quorum-sensing inhibitor of uropathogen Proteus mirabilis.

Younis K, Usup G, Ahmad A Environ Sci Pollut Res Int. 2015; 23(5):4756-67.

PMID: 26538254 DOI: 10.1007/s11356-015-5687-9.


Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases.

Zeitlin L, Cone R, Whaley K Emerg Infect Dis. 1999; 5(1):54-64.

PMID: 10081672 PMC: 2627706. DOI: 10.3201/eid0501.990107.


Characterization of Bartonella bacilliformis flagella and effect of antiflagellin antibodies on invasion of human erythrocytes.

Scherer D, Minnick M Infect Immun. 1993; 61(12):4962-71.

PMID: 8225570 PMC: 281270. DOI: 10.1128/iai.61.12.4962-4971.1993.


Proteus mirabilis flagella and MR/P fimbriae: isolation, purification, N-terminal analysis, and serum antibody response following experimental urinary tract infection.

Bahrani F, Johnson D, Robbins D, Mobley H Infect Immun. 1991; 59(10):3574-80.

PMID: 1680106 PMC: 258923. DOI: 10.1128/iai.59.10.3574-3580.1991.


Ability of Proteus mirabilis to invade human urothelial cells is coupled to motility and swarming differentiation.

Allison C, Coleman N, Jones P, Hughes C Infect Immun. 1992; 60(11):4740-6.

PMID: 1398984 PMC: 258226. DOI: 10.1128/iai.60.11.4740-4746.1992.

References
1.
Sawada S, Kawamura T, Masuho Y, Tomibe K . Characterization of a human monoclonal antibody to lipopolysaccharides of Pseudomonas aeruginosa serotype 5: a possible candidate as an immunotherapeutic agent for infections with P. aeruginosa. J Infect Dis. 1985; 152(5):965-70. DOI: 10.1093/infdis/152.5.965. View

2.
Gigliotti F, Insel R . Protection from infection with Haemophilus influenzae type b by monoclonal antibody to the capsule. J Infect Dis. 1982; 146(2):249-54. DOI: 10.1093/infdis/146.2.249. View

3.
Coughlin R, Bogard Jr W . Immunoprotective murine monoclonal antibodies specific for the outer-core polysaccharide and for the O-antigen of Escherichia coli 0111:B4 lipopolysaccharide (LPS). J Immunol. 1987; 139(2):557-61. View

4.
MONTIE T, Craven R, Holder I . Flagellar preparations from Pseudomonas aeruginosa: isolation and characterization. Infect Immun. 1982; 35(1):281-8. PMC: 351027. DOI: 10.1128/iai.35.1.281-288.1982. View

5.
Hancock R, Mutharia L, Mouat E . Immunotherapeutic potential of monoclonal antibodies against Pseudomonas aeruginosa protein F. Eur J Clin Microbiol. 1985; 4(2):224-7. DOI: 10.1007/BF02013602. View